American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • 2017
  • »
  • July

ESSA Pharma presents data from clinical trial for anti-tumor drug

American Pharmacy News Reports | Jul 14, 2017
Prostate cancer is the second-most common cancer in men.

ESSA Pharma Inc. recently announced early data from its Phase 1 clinical trial for EPI-506, an anti-tumor drug. Read More »

Aridis Pharmaceuticals shares results for pneumonia drug

American Pharmacy News Reports | Jul 14, 2017
The new, antibody-based immunotherapy toward late-stage clinical studies is a priority for Aridis.

Aridis Pharmaceuticals Inc. recently announced positive results for its Phase 2a trial of Salvecin for treating severe pneumonia caused by Staphylococcus aureus. Read More »

GeoVax's Lassa fever vaccine test shows promising results

American Pharmacy News Reports | Jul 15, 2017
The mice were vaccinated with GEO-LM01, then infected with LASV.

GeoVax announced promising results in testing a Lassa hemorrhagic fever vaccine (LASV) in mice. Read More »

Final Phase III trial on Praxbind produces positive results

American Pharmacy News Reports | Jul 15, 2017
The U.S. Food and Drug Administration approved Praxbind under accelerated conditions.

Final study shows immediate reversal of Pradaxa; anticoagulant drug's effect negated by Praxbind. Read More »

Parkinson's add-on medication XADAGO approved for use in U.S.

American Pharmacy News Reports | Jul 15, 2017
Patients on once-daily XADAGO demonstrated significant improvement in ‘on’ time without troublesome dyskinesia.

Helps reduce Parkinson's symptoms when primary medications are not completely effective; patients' voluntary movements not impaired by addition of XADAGO. Read More »

CVS MinuteClinic teams with Alere to expand services

American Pharmacy News Reports | Jul 15, 2017
MinuteClinics offer work-required physicals, screenings, tests and immunizations.

Certain workplace necessities just became easier for employees seeking routine screenings and basic health care services thanks to a partnership between CVS MinuteClinic and Alere eScreen Occupational Health Network (EOHN) expanding access via participating locations. Read More »

Sci-B-Vac Hepatitis B vaccine set to begin global Phase 3 trials

American Pharmacy News Reports | Jul 19, 2017
The trials will be conducted at 40 sites in the U.S., Canada and Europe.

Two third generation hepatitis B vaccine trials to enroll 4,800 participants in the U.S., Canada and Europe. Read More »

DelMar Pharmaceuticals adds Zarrabian, Mohr to board

American Pharmacy News Reports | Jul 19, 2017
DelMar President and CEO Jeffrey Bacha had also served as chairman since 2010.

DelMar Pharmaceuticals of Vancouver, British Columbia recently appointed two individuals to its board of directors, in alignment with its mission both to strengthen the board and to allow for expansion of its current executive’s scope. Read More »

Takeda, Seattle Genetics net positive results for Phase 3 study of Adcetris

American Pharmacy News Reports | Jul 19, 2017
The Echelon-1 trial -- a randomized, multicenter study -- evaluated the effects on 1,334 patients using Adcetris.

Takeda Pharmaceuticals Ltd. and Seattle Genetics Inc. recently announced that their Adcetris drug, which was created to treat advanced Hodgkin lymphoma, met its primary endpoint during the Phase 3 Echelon-1 clinical trial. Read More »

Rennova Health to spin off AMSG division to public ownership

American Pharmacy News Reports | Jul 19, 2017
Rennova’s board of directors previously authorized a spinoff of its Health Technology Solutions business.

Via tax-free allotment to company shareholders, Rennova Health Inc. intends to transition its Advanced Molecular Services Group to a publicly traded entity by late September pending appropriate paperwork with the SEC and other conditions. Read More »

Bill to regulate pharmacy benefit managers advances in California

John Breslin | Jul 19, 2017
The California bill requires PBMs to annually obtain a license from the Department of Managed Health Care.

A bill mandating pharmacy benefit managers obtain a license to conduct business in California and release information to health plans and other purchasers is moving through the state's legislature. Read More »

Elsevier’s ‘Hive’ 2017 to feature biotech, pharma startups

American Pharmacy News Reports | Jul 19, 2017
Pre-revenue biotech, pharma and other small companies involved in early stage research with at least 10 scientists on staff are eligible.

Specialists at information analytics company Elsevier recently announced that its 2017 season for “The Hive,” its source for rising biotech and pharmaceutical companies, is gearing up with unlimited nomination spots now open for aspiring entrants. Read More »

Sanofi, Regeneron release positive results for carcinoma inhibitor

American Pharmacy News Reports | Jul 19, 2017
REGN2810 is also being evaluated in a Phase 2 study.

Sanofi and Regeneron Pharmaceuticals Inc. recently announced positive results for a Phase 1 study evaluating investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1) in patients with advanced cutaneous squamous cell carcinoma. Read More »

PCMA proposes policy to slash prescription prices

Carol Ostrow | Jul 19, 2017

Suggesting ways to reduce prescription drug costs plus overall marketplace guidance, the Pharmaceutical Care Management Association recently wrote to Health and Human Services Secretary Tom Price, detailing potential pricing and savings allocation improvements. Read More »

West Pharmaceutical Services presents at InnoPack Pharma Confex

American Pharmacy News Reports | Jul 21, 2017
The presentation capped a weeklong series of seminars and educational activities.

West Pharmaceutical Services Inc. presented on best practices for improving patient outcomes through integrated containment and delivery systems at the Sixth Annual InnoPack Pharma Confex in Mumbai, India. Read More »

Amgen reports primary endpoint success for Phase 2 study

American Pharmacy News Reports | Jul 21, 2017
The combination more than doubled objective response rate in patients with unresectable Stage IIIB-IV melanoma.

Amgen's Phase 2 study evaluating Imlygic combined with Yervoy as a treatment for patients with unresectable Stage IIIB-IV met its​ primary endpoint. Read More »

Merck to partner with F-Star on bispecific immuno-oncology antibodies

American Pharmacy News Reports | Jul 21, 2017
Merck will be able to replace and add to these antibodies by using F-Star’s bispecific antibody platform.

Merck KGaA will collaborate with F-Star, a biopharmaceutical company in the United Kingdom, to develop and commercialize five bispecific immuno-oncology antibodies. Read More »

Amgen releases positive results for Xgeva Phase 3 study

American Pharmacy News Reports | Jul 21, 2017
Patients treated with Xgeva had fewer renal adverse events compared to those treated with zoledronic acid.

Amgen's Xgeva Phase 3 study, the largest international multiple myeloma trial ever conducted, met its primary endpoint by demonstrating that the drug is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Read More »

Phase 3 trial shows Imbruvica benefits leukemia patients

American Pharmacy News Reports | Jul 21, 2017
Study results show continued survival rates in patients with chronic lymphocytic leukemia for up to four years.

AbbVie recently announced positive follow-up results for its pivotal Phase 3 Resonate trial, which evaluated Imbruvica as a treatment for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Read More »

HedgePath Pharma seeks FDA guidance on its SUBA-Cap trial

American Pharmacy News Reports | Jul 21, 2017
Thirty-seven percent of patients in the Phase 2(b) trial have demonstrated an equal to or greater than 30 percent reduction in target tumor burden.

HedgePath Pharmaceuticals Inc. (HPPI) recently announced that the U.S. Food and Drug Administration (FDA) granted the company’s Type-C Guidance Meeting Request for further guidance on HPPI’s Phase 2(b) clinical trial analyzing SUBA-Itraconazole (SUBA-Cap) oral capsule usage in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. Read More »

  • «
  • 1
  • 2
  • 3 (current)
  • 4
  • 5
  • »
Trending

Dr. Allison Hill DC State Board of Pharmacy Chairperson

Modified services and closures announced for DC Emancipation Day observance

 Jeff Harrell Board President

Arkansas law bans PBMs from pharmacy ownership to curb anti-competitive practices

Shaun Noorian, Founder, CEO & Chairman, Empower Pharmacy

Empower Pharmacy ranks among fastest-growing private firms in Southwest

 Jeff Harrell Board President

NCPA reacts to Trump's drug pricing executive order targeting pharmacy benefit managers

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up